Stockscreener 앱 받기
128.31
5.25%
6.40
시간 외 거래:
130.00
1.69
+1.32%
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Mirum Pharmaceuticals outlines its liver disease focus as shares trade on Nasdaq - AD HOC NEWS
RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating - marketscreener.com
Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM) - Stock Titan
Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM) - Stock Titan
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio - Seeking Alpha
MIRMMirum Pharmaceuticals Inc Latest SEC Filings - Finviz
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum Pharmaceuticals SVP sells $326,520 in common stock By Investing.com - Investing.com South Africa
Form 4 Mirum Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Mirum Pharmaceuticals SVP sells $326,520 in common stock - Investing.com
Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD - Investing.com
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125 - Moomoo
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib - Yahoo Finance
Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
2,721 performance shares proposed; Jolanda Howe sold 2,594 (MIRM) - Stock Titan
Mirum Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Fischer Laurent - Moomoo
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength? - Yahoo Finance
5 Biotech Stocks That Skyrocketed 105% To 235% — TWST, INDV, MIRM & More - RTTNews
Mirum Pharmaceuticals Stock Surges 25%, With A 9-Day Winning Spree - Trefis
Enterprise value to EBITDA forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to book forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN
Enterprise value to revenue forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to sales forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Understanding Momentum Shifts in (MIRM) - Stock Traders Daily
Price to earnings forward of Mirum Pharmaceuticals, Inc. – HAM:08D - TradingView
9-Day Rally Sends Mirum Pharmaceuticals Stock Up 25% - Trefis
MIRM, INCY report positive rare disease data as FDA begins NDA review - MSN
MIRM Forecast — Price Target — Prediction for 2027 - TradingView
Mirum Pharmaceuticals Stock Surges 18%, With A 8-Day Winning Spree - Trefis
MIRM Technical Analysis & Stock Price Forecast - Intellectia AI
Mirum Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRM) - TradingView
08D Forecast — Price Target — Prediction for 2027 - TradingView
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data? - Insider Monkey
10 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
Mirum Pharmaceuticals stock hits all-time high at 114.99 USD By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock hits all-time high at 114.99 USD - Investing.com
Mirum Pharmaceuticals stock pushes toward 52-week high amid strong bullish momentum - Traders Union
Values First Advisors, Inc.'s Mirum Pharmaceuticals Inc(MIRM) Holding History - GuruFocus
Mirum Shareholders Approve Directors, Auditors and Compensation - The Globe and Mail
Mirum Pharmaceuticals StockAnalyst views and sector check at week’s end - AD HOC NEWS
Mirum (MIRM) SVP Jolanda Howe sells 2,594 shares under Rule 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals, Inc. (MIRM) reports Q1 loss, beats revenue estimates - MSN
Mirum Pharmaceuticals (MIRM) stockholders back 2026 directors, auditor and pay package - Stock Titan
Mirum Pharmaceuticals Inc (MIRM) Institutional Confidence - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
1.17%
2.48%
자본화:
|
볼륨(24시간):